TY - JOUR

T1 - A pharmacological profile of the high-affinity GluK5 kainate receptor

AU - Møllerud, Stine

AU - Kastrup, Jette Sandholm Jensen

AU - Pickering, Darryl S

PY - 2016

Y1 - 2016

N2 - Mouse GluK5 was expressed in Sf9 insect cells and radiolabelled with [3H]-kainate in receptor binding assays (Kd = 6.9 nM). Western immunoblotting indicated an Sf9 GluK5 band doublet corresponding to the glycosylated (128 kDa) and deglycosylated (111 kDa) protein, which was identical to the band pattern of native rat brain GluK5. A pharmacological profile of the high-affinity kainate receptor GluK5 is described which is distinct from the profiles of other kainate receptors (GluK1-3). The 27 tested ligands generally show a preferential affinity to GluK1 over GluK5, the exceptions being: dihydrokainate, (S)−5-fluorowillardiine (S)-glutamate and quisqualate, where the affinity is similar at GluK1 and GluK5. In contrast, quisqualate shows 40-fold higher affinity at GluK5 over GluK3 whereas (S)−1-(2’-amino-2’-caboxyethyl)thienol[3,4-d]pyrimidin-2,4-dione (NF1231), (RS)−2-amino-3-(5-tert-butyl-3-hydroxyisoxazol-4-yl)propionate (ATPA), dihydrokainate and (2 S,4 R)−4-methyl-glutamate (SYM2081) have higher affinity at GluK3 compared to GluK5. Since some studies have indicated that GluK5 is associated with various diseases in the central nervous system (e.g. schizophrenia, temporal lobe epilepsy, bipolar disorder), selective GluK5 ligands could have therapeutic potential. The distinct pharmacological profile of GluK5 suggests that it would be possible to design ligands with selectivity towards GluK5.

AB - Mouse GluK5 was expressed in Sf9 insect cells and radiolabelled with [3H]-kainate in receptor binding assays (Kd = 6.9 nM). Western immunoblotting indicated an Sf9 GluK5 band doublet corresponding to the glycosylated (128 kDa) and deglycosylated (111 kDa) protein, which was identical to the band pattern of native rat brain GluK5. A pharmacological profile of the high-affinity kainate receptor GluK5 is described which is distinct from the profiles of other kainate receptors (GluK1-3). The 27 tested ligands generally show a preferential affinity to GluK1 over GluK5, the exceptions being: dihydrokainate, (S)−5-fluorowillardiine (S)-glutamate and quisqualate, where the affinity is similar at GluK1 and GluK5. In contrast, quisqualate shows 40-fold higher affinity at GluK5 over GluK3 whereas (S)−1-(2’-amino-2’-caboxyethyl)thienol[3,4-d]pyrimidin-2,4-dione (NF1231), (RS)−2-amino-3-(5-tert-butyl-3-hydroxyisoxazol-4-yl)propionate (ATPA), dihydrokainate and (2 S,4 R)−4-methyl-glutamate (SYM2081) have higher affinity at GluK3 compared to GluK5. Since some studies have indicated that GluK5 is associated with various diseases in the central nervous system (e.g. schizophrenia, temporal lobe epilepsy, bipolar disorder), selective GluK5 ligands could have therapeutic potential. The distinct pharmacological profile of GluK5 suggests that it would be possible to design ligands with selectivity towards GluK5.

U2 - 10.1016/j.ejphar.2016.06.049

DO - 10.1016/j.ejphar.2016.06.049

M3 - Journal article

C2 - 27373850

VL - 788

SP - 315

EP - 320

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -